Background-We investigated the role of phenotypic characteristics in stratifying the risk of sustained ventricular arrhythmias in patients harboring arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutations. Methods and Results-Clinical, electrocardiographic, and arrhythmic outcome (composite measure of first occurrence of sustained ventricular tachycardia/resuscitated sudden cardiac death/sudden cardiac death/appropriate implantable cardioverter-defibrillator therapy) data were obtained for 215 patients (104 families; 85% PKP-2). During a mean follow-up of 7 years, 86 (40%) patients experienced the arrhythmic outcome. Event-free survival was significantly lower among probands (P<0.001) and symptomatic (P<0.001) patients. Integration of ECG repolarization and depolarization abnormalities allowed for differential risk categorization. Event-free survival at 5 years for the low-risk ECG group (0-1 T inversions or minor depolarization changes) was 97% versus 81% for the intermediate-risk ECG group (2 T inversions+minor depolarization changes) versus 33% for the high-risk ECG group (≥3 T inversions±major or minor depolarization changes; P<0.001). Incremental arrhythmic risk was seen in patients with increasing premature ventricular complex count on a Holter (P<0.001). Proband status (hazard ratio, 7.7; 95% confidence interval, 2.8-22.5; P<0.001), ≥3 T-wave inversions (hazard ratio, 4.2; 95% confidence interval, 1.2-14.5; P=0.035), and male sex (hazard ratio, 1.8; 95% confidence interval, 1.2-2.8; P=0.004) were independent predictors of the first arrhythmic event on multivariable analysis. Conclusions-Pedigree evaluation, an ECG, and a Holter examination provide for comprehensive arrhythmic risk stratification in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutations. We propose an approach to risk stratification based on these variables. (Circ Arrhythm Electrophysiol. 2013;6:569-578.) The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/
A rrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy, characterized predominantly by ventricular arrhythmias, right ventricular dysfunction, and risk of sudden cardiac death (SCD). 1 Beginning with the seminal discovery of mutations in plakaglobin as the genetic basis of Naxos disease in 2000, 2 the past decade has witnessed the identification of mutations in 5 desmosomal proteins causing or contributing to ARVD/C. [2] [3] [4] [5] [6] These desmosomal genes include Plakophilin 2 (PKP2), Desmoplakin (DSP), Desmoglein 2 (DSG2), Desmocollin 2 (DSC2), and Plakoglobin (JUP). Mutations in several nondesmosome genes have also been reported to cause ARVD/C: Transmembrane protein 43 (TMEM43), 7 Desmin (DES), 8 Titin (TTN), 9 transforming growth factor-beta3 (TGFB3), 10 and Phospholamban (PLN). 11 Clinical expression among mutation carriers is often variable, and widespread use of commercial genetic testing has resulted in increased recognition that there is not a direct correlation of the presence of a desmosomal mutation with life-threatening arrhythmias. [12] [13] [14] [15] Current guidelines recommend screening of genetically affected family members using a combination of electrocardiographic, Holter and right ventricular imaging modalities. 16 It is essential to be able to identify prognostic markers of arrhythmic risk from these clinical parameters that are commonly used to characterize the ARVD/C phenotype. However, because of the fact that cardiac events seem to be unpredictable in patients with ARVD/C, 17 and because clinical genetic testing is a recent phenomenon, 18 the optimal approach to arrhythmic risk stratification among desmosomal mutation carriers is not well defined.
The objectives of this study were 3-fold. First, we aimed to characterize the arrhythmic risk spectrum in a large cohort of ARVD/C-associated mutation carriers. Second, we investigated phenotypic characteristics that are associated with a differential risk of developing sustained ventricular arrhythmias. Finally, we sought to identify noninvasive markers of arrhythmic risk that would be of value in determining which ARVD/C-associated mutation carriers merit further invasive risk stratification, more intense follow-up, and placement of an implantable cardioverter-defibrillator (ICD).
Methods

Patient Population
The patient population comprised of 215 patients from 104 families enrolled in the Johns Hopkins ARVD/C registry who were identified as harboring an ARVD/C-associated mutation. All those in the registry who presented while alive, underwent mutational analysis with identification of a pathogenic ARVD/C-associated mutation, and documentation of clinical outcomes were included in the study. All subjects gave written informed consent to participate in this study, which was approved by The Johns Hopkins School of Medicine Institutional Review Board.
Clinical Phenotype
The medical history of each subject was obtained by review of medical records, clinical evaluation, and patient interview. Detailed clinical information about demographics, presentation, symptoms, medication use, noninvasive and invasive studies, and arrhythmia occurrence was obtained for each patient. The presence of repolarization (number of inverted precordial T-waves) and depolarization (epsilon waves: reproducible low-amplitude signals between end of QRS complex and onset of the T wave in the right precordial leads [V1 to V3]; terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R prime in V1, V2, or V3, in the absence of complete right bundle-branch block) abnormalities on the ECG were determined. T waves that were flat in the precordial leads were not considered as inverted. All ECGs were recorded at rest (10 mm/mV in speed 25 mm/s) at the standard lead positions, and proper location of the precordial electrodes on the chest was ensured. No individual was receiving antiarrhythmic or other drugs known to affect the QRS complex at the time of acquisition of the ECG tracings. Late potentials by signal-averaged ECG (using time-domain analysis with a bandpass filter of 40 Hz) in ≥1 of 3 parameters in the absence of a QRS duration of >110 ms on the standard ECG were considered abnormal. Echocardiographic and MRI tests were reviewed (H.T., T.A.) for structural abnormalities to determine the severity and extent of right ventricular dysfunction and categorized as normal, abnormal not meeting criteria, minor abnormality, 19 and major abnormality 19 (see Methods in the online-only Data Supplement for definitions). A detailed family history was obtained through patient interview by genetic counselors with special interest in ARVD/C for pedigree analysis. The proband was the first affected family member seeking medical attention for ARVD/C, in whom the diagnosis was confirmed (ie, an affected person ascertained independently of family history of ARVD/C), whereas the rest were family members (individuals ascertained through family screening). Comprehensive mutation testing was performed for all probands through commercial or research genetic testing. 12 Family members were screened specifically for the mutation identified in the proband (see Table 1 in the online-only Data Supplement for mutation details).
Subsequent to the initial enrollment, patients were prospectively followed up at yearly intervals, and information about major clinical events was collected (events included syncope, episodes of sustained ventricular tachycardia [VT] or fibrillation, resuscitated SCD, ICD implantation, appropriate ICD discharges, catheter ablation, electrical storm, heart failure, cardiac transplantation, SCD, and other causes of death ascertained; see Methods in the online-only Data Supplement for definitions). This information was obtained from referring institutions and individual patients and recorded by age. Of the 215 study patients, 64 were included in earlier investigations 13, 14 and are reported with extended follow-up. The diagnosis of ARVD/C was based on the presence of major and minor diagnostic criteria according to the 2010 revised task force criteria (TFC). 19 Tissue characterizations from biopsies were not taken into account, because morphometric analyses had not been performed as prescribed in the 2010 TFC. 19 
Outcome
The primary outcome measure was the occurrence of a sustained arrhythmic event (a composite measure of the occurrence of SCD, resuscitated SCD, spontaneous sustained VT, or an appropriate ICD intervention for a sustained ventricular arrhythmia). In patients with multiple end points, the first event was considered the censoring event.
Statistical Analysis
Continuous variables are summarized as either mean±SD or median (interquartile range) and compared across groups using a t test or Mann-Whitney U test. Categorical variables are reported as frequency (%) and compared between groups by the χ 2 or Fisher exact test. The cumulative probability of arrhythmic outcome-free survival was determined by the Kaplan-Meier method, and differences in survival between groups were evaluated with the log-rank test. Multivariable Cox regression analysis was used to identify relevant clinical, electrocardiographic, and phenotypic variables associated with occurrence of the arrhythmic outcome using SPSS version 19.0 (IBM, Chicago, IL). The electrocardiographic risk stratification was based on the number of precordial T wave inversions in V1-V6 regardless of which precordial leads. No analysis combining genotype (gene, type of mutations, etc) and clinical phenotype, including arrhythmic risk, was performed because this was not a genotype-phenotype study. The prognostic role of inducibility at an EP study was not evaluated because this invasive test was performed in less than half of the population. Within family dependency was evaluated by using a robust variance estimator, clustered by family. A P value <0.05 was considered significant. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the article as written.
Results
Study Population
The clinical characteristics of the 215 patients (88 probands and 127 family members) with ARVD/C-associated mutations who participated in this study are summarized in Table 1 . One hundred and twenty-eight patients were classified as definite ARVD/C by the revised TFC 19 ( Table 2 in the online-only Data Supplement). Mutations in PKP2 were the most commonly identified desmosomal mutations (n=182; 85%).
Arrhythmic Outcome
Eighty-six (40%) patients experienced the primary arrhythmic outcome as defined above ( Table 2 ). The event-free survival at 5 and 15 years of follow-up was 58% and 40%, respectively. The average age at time of first arrhythmic episode was 32±11 years ( Figure 1A ). No event was experienced before the age of 14 years with 6 patients encountering their first episode after the age of 50 years.
Risk Factors
Clinical Presentation
Sustained VT (n=45) or ventricular fibrillation (n=5) was observed at presentation in 50 (23%) patients. The mean cycle length of the VT was 270±43 ms (range 200-394). The first VT episode had a cycle length (CL) >320 ms (median CL 353) in 6 patients, although none had a CL >400 ms. Among patients that did not have a sustained arrhythmia at presentation; 13 (8%) developed sustained VT, 3 (2%) were resuscitated from SCD, and 19 patients (11.5%) received an appropriate ICD intervention for treatment of a sustained ventricular arrhythmia (VT/ventricular fibrillation) during follow-up.
Among these patients, being symptomatic at presentation was a significant predictor of sustained arrhythmia occurrence during follow-up (P<0.001).
Probands experienced significantly higher number of events and lower cumulative event-free survival than family members (77 [86.5%] versus 9 [7.1%]; P<0.001; Table 2 ). Family members symptomatic at presentation had significantly lower event-free survival than asymptomatic participants ( Figure 1B ). Female family members experienced their first event at a later age (median 40 [7.1]) as compared with males (median 30 [18.2] ). Other than this difference, no other sexrelated differences in event-free survival were observed. Among family members, no participant experienced an arrhythmic event before the age of 20 years, and no resuscitated or fatal SCD events were seen during follow-up.
ECG Findings
As shown in Figure 1A in the online-only Data Supplement, increasing number of inverted precordial T-waves were associated with increasing proportion of subjects experiencing an arrhythmic event. Patients with ≥3 precordial inverted T-waves demonstrated significantly increased arrhythmic risk compared with participants with T-wave inversion on only 1 or 2 right precordial leads ( Figure 1B in the onlineonly Data Supplement). Arrhythmic events among family members occurred only in patients with ≥3 T inversions. An incremental risk pattern with increasing number of precordial T inversions was also seen for the occurrence of VT storms, appropriate ICD interventions, and NSVT (Figure 2A , 2B, and 2C in the online-only Data Supplement). As shown in the online-only Data Supplement Figure 3 , the presence of either a major depolarization abnormality (Epsilon waves and QRS >110 ms in right precordial leads; n=22 [10%]) or minor depolarization abnormality (terminal activation duration and late potentials on signal-averaged ECG; n=77 [36%]) was associated with a significantly increased proportion of patients experiencing arrhythmic outcome and a lower event-free survival.
Composite ECG Assessment
As shown in Figure 2A and 2B, an incremental arrhythmic risk pattern was seen when repolarization and depolarization abnormalities were integrated, allowing for differential risk categorization based on a composite ECG assessment. Patients with ≥3 inverted precordial T-waves with or without a depolarization abnormality demonstrated the highest arrhythmic risk, whereas those with an isolated depolarization abnormality or T-wave inversions in leads V1 and V2 and minor depolarization abnormalities (terminal activation duration or late potentials) represented the intermediate-risk pattern. The lowest risk group included patients with 0 to 2 T-wave inversions without any depolarization changes. The cumulative survival at 10 years for the low-risk group was 97% versus 81% for the intermediate group versus 21% for the high-risk group (P<0.001). As seen in Figure 2C , no family member with a low-or intermediate-risk ECG pattern experienced an arrhythmic event during follow-up. In probands, as the ECG risk pattern worsened, the arrhythmia-free survival at 5 years declined (intermediate risk: 33%; high risk: 17%).
Holter Monitoring
The premature ventricular complex (PVC) burden on 24-hour Holter monitoring was significantly higher in those participants who experienced an arrhythmic outcome (Table 1 ; P<0.001). As seen in Figure 3A , when the cumulative eventfree survival was analyzed according to the quartile of PVC count, there was a progressive decrease in event-free survival at higher PVC burden, demonstrating an increased probability of a first arrhythmic event among patients with PVC count in the upper quartiles compared with those with fewer PVCs. Among probands with a low-or highrisk ECG pattern, PVC count on a Holter did not identify differential risk. As shown in Figure 3B , in patients with an intermediate-risk ECG, the PVC count was higher in those experiencing an arrhythmic outcome as compared with those who remained free of an arrhythmic event, with a PVC count of 760 differentiating the 2. Among family members with a high-risk ECG pattern (the only family member group with events), PVC quartiles had incrementally lower event-free survival ( Figure 3C ). Figure 4A in the online-only Data Supplement shows the relationship between presence of a structural abnormality (as determined by the revised 2010 TFC) 20 and the risk of an arrhythmic event in the study population. Five (7.5%) patients with normal imaging experienced arrhythmic events, while 34% of those with structural abnormalities not fulfilling revised TFC 20 also had an arrhythmic outcome. As seen in previous studies, 20 worsening structural abnormalities were underscored by progression in the extent of ECG abnormalities ( Figure 4B in the online-only Data Supplement). Within each structural group, the presence of a high-risk ECG was associated with higher event rate, while a low-risk ECG conferred a benign arrhythmic course ( Figure 4C in the onlineonly Data Supplement).
Imaging
Development of a Risk-Prediction Scheme
To assess the significance and independence of the predictors of the occurrence of a first arrhythmic event among ARVD/Cassociated desmosomal mutation carriers, we entered clinically relevant variables: sex, pedigree, nature of presentation, syncope, precordial T-wave inversions, depolarization abnormalities, family history of SCD, family history of ARVD/C, LV dysfunction, and right ventricular structural abnormality in a Cox regression model. Ranking the cumulative probability yielded a risk-stratification scheme that may guide therapeutic strategies in patients with the ARVD/C-associated desmosomal mutations whose genotypes have been determined (Figure 4) 
Discussion
Genetic testing for ARVD/C-associated desmosomal gene mutations is now commonly available and recommended for cascade screening among family members as per recent guidelines. 16 As a result, more patients are being identified as mutation carriers and are interested in defining their arrhythmic risk in terms of intensity of follow-up and ICD placement. By investigating our large database of unselected, consecutively genotyped patients and by analyzing the incidence of arrhythmic events, we were able to characterize the incidence of sustained ventricular arrhythmias and identify differential risk among mutation carriers. Because of the significant cost, frequent inaccurate interpretation, and lack of expertise in evaluation of MRIs, 21 we focused on more easily obtained clinical parameters. By pedigree, we developed a risk-stratification scheme among desmosomal mutation carriers with possible implications for disease management.
Previous Studies
There are no prospective and controlled studies assessing clinical markers solely among mutation carriers, which can predict the occurrence of sustained ventricular arrhythmias. The noninvasive risk profile generated from previous retrospective clinical and pathological risk-stratification studies have had considerable limitations: small series, 14, 22 selection of severe phenotype, [22] [23] [24] surrogate ICD outcomes, 22, 25, 26 unknown genetic substrate, 27 and absence of long-term survival analysis. 23, 24 In addition, previous studies 28 have often used nonarrhythmic outcomes, lack information on pedigree, or Holter ectopy and have not attempted integration of repolarization and depolarization abnormalities, limiting their direct prognostic application in the current era. Additionally, during the past 5 years, widespread application of genetic testing has led to appreciation of a broad arrhythmic risk spectrum among desmosomal mutation carriers necessitating elucidation of a novel discriminative paradigm.
Main Outcomes
There were 4 main findings of this study. We demonstrated a high incidence of sustained ventricular arrhythmias among desmosomal mutations carriers, with 40% experiencing the arrhythmic outcome and nearly one quarter presenting with sustained arrhythmias. Importantly, our study demonstrates that this risk is age dependent and intimately related to the age of the patients. Also, the arrhythmic propensity of the proband (index case) must not necessarily be applied to at-risk family members who by virtue of low penetrance of this disease are at a different and lower level of risk. Our study shows that development of symptoms of syncope, presyncope, and palpitations increased the risk of sustained arrhythmic event among family members. We demonstrate that the extent of repolarization abnormalities manifested by inverted precordial T-waves can be considered a novel index of repolarization heterogeneity and, consequently, arrhythmic risk. Our study shows in a unique manner that an incremental relationship exists between occurrence of arrhythmic events and the number of inverted precordial T-waves with ≥3 inverted T-waves being an independent predictor of outcome. These easily observed and reliable abnormalities seem to be particularly key markers of arrhythmic vulnerability among family members with mutations. These data are consistent with the central role of repolarization abnormalities in arrhythmogenesis observed not only among heart failure 29 and postmyocardial infarction patients, 30 but also in previous smaller ARVD/C cohorts. 23, 24 More recently, postpubertal persistence of T-wave inversions had been associated with the diagnosis of ARVD/C in asymptomatic children. 31 In our study population, presence of a major or minor depolarization abnormality was also seen to confer increased risk. However, patients without any depolarization abnormalities also had low event-free survival, suggesting that this parameter is not a good discriminator on its own but may add adjunctive refinement to repolarization abnormalities.
Our study shows that integrating both repolarization and depolarization elements revealed a differential risk spectrum, allowing for categorization into high-, intermediate-, and low-risk ECG patterns based on freedom from lifethreatening ventricular arrhythmias. No family member with a low-or intermediate-risk ECG pattern experienced any outcome events. The arrhythmic incidence among the electrocardiographic high-risk group was 50-fold higher than in the low-risk group of desmosomal mutation carriers, allowing potential for individualizing treatment options based on the ECG. Finally, our study shows incremental risk of sustained ventricular arrhythmias among mutation carriers because the PVC count increases especially among higher quartiles of the ectopy burden. Frequent ectopy is a relatively common manifestation of the ARVD/C phenotype. 21 Recently, increased ventricular ectopy as measured on a 24-hour Holter monitoring has been suggested as a marker of electric instability and future appropriate ICD therapy. 26 Our study demonstrates in a unique manner that this finding is especially pertinent for family members with a high-risk ECG where arrhythmia propensity is incrementally related to increasing PVC count. Also, in probands with an intermediate-risk ECG, upper quartiles of ectopy (>760 PVC) seem to confer a high arrhythmic risk. Our study points to the key novel role of PVC monitoring to determine sustained arrhythmia risk among ARVD/C mutation carriers.
We, therefore, propose a novel risk-stratification scheme based on pedigree, ECG, and Holter monitoring for evaluation of the risk of sustained arrhythmias among ARVD/Cassociated desmosomal mutation carriers. This integrative approach using commonly available, noninvasive tests based on the risk factors identified in this study allows for determination of optimal therapies for individual patients based on their arrhythmic risk category.
Limitations
Our study has some limitations. First, the results need to be interpreted in context of the biases attributable to the retrospective component of the study. Because we only included mutation carriers in this analysis, we could not test for the possibility that the presence of a mutation adds to the arrhythmic risk as compared with patients with ARVD/C and no discernible mutation. Also, because 85% of patients had PKP-2 mutations, the data may not be generalized for other ARVD/C populations where DSP or other genes are more often represented. Second, the use of appropriate ICD therapy (19 patients) as a surrogate marker for SCD may overestimate the arrhythmic risk. However, the mean CL of the VT in these 19 patients was 256±40 ms with half of the VT episodes having CL <250 ms. Third, the arrhythmic propensity may likely change over time because patients develop progressive ECG changes or Holter ectopy, necessitating not only periodic reevaluation but restratification, especially family members with low-to intermediate-risk ECG. Fourth, an important limitation of the quantitative parameters (especially terminal activation duration and QRS duration >110 ms) used for establishment of a diagnosis of ARVD/C in both the 1994 and 2010 diagnostic criteria and for risk stratification in this article is inconsistent intrareader and inter-reader reproducibility, regardless of whether the ECG is recorded using standard settings, double speed, double amplitude, or using EL. 32 This is a limitation of this study, and of all studies of ARVD/C that adhere to the 2010 diagnostic criteria. In contrast to the assessment of the quantitative parameters used for the establishment of a diagnosis of ARVD/C, we have previously reported that the presence or absence of T-wave inversion in the right precordial leads is a highly reproducible parameter. 32 Also, because only 9 events occurred among family members, we have no effective power to evaluate risk factors solely among family members or the interactions by proband status. Finally, the true significance of this novel risk stratification scheme requires validation of these findings in the future in similar global cohorts and in patients without an identified genetic abnormality.
Conclusions
Among a large cohort of North American patients with ARVD/C-associated mutations, we demonstrate incomplete although age-dependent arrhythmic penetrance and identify clinical risk factors. Our study shows that electrocardiographic repolarization and depolarization abnormalities potently reflect arrhythmic susceptibility among these patients and allow for differential risk categorization. Our study shows in a unique manner that an incremental risk of sustained ventricular arrhythmias exists among mutation carriers because the PVC count increases especially among higher quartiles of PVC burden. We propose a novel approach to risk stratification based on commonly available diagnostic modalities used to characterize the phenotype in patients with ARVD/Cassociated mutations, facilitating the management of these patients. According to this risk-stratification system, low-risk ARVD/C-associated mutation carriers are family members with a low-or intermediate-risk ECG and also family members with a high-risk ECG and <10 PVC on a 24-hour Holter monitoring. We would propose this subset of patients not to undergo ICD implantation but rather be followed up with serial clinical evaluations. In contrast, we would advise ICD implantation for ARVD/C-associated mutation carriers who fall into the intermediate-and high-risk groups.
